MBX Biosciences Inc. (MBX)
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 54.54 0.00%
MBX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.63B
- EPS (TTM)
- -$2.37
- Dividend yield
- None
- 52-week range
- 12.94 – 72.64
- Day range
- 53.36 – 58.50
- Volume / Avg
- 355.11K / 556.72K
- Beta
- —
- Shares outstanding
- 48.16M
- Next earnings
- Nov 5, 2026
52-week range
MBX stock today
MBX Biosciences (MBX) closed at $54.54 on Oct 7, down 4.18% (-$2.38), versus the S&P 500's 0.22% decline. Shares are 24.9% below their 52-week high of $72.64, set on Aug 5, 2026 and 321.5% above the 52-week low of $12.94, in the middle of the past year's range. MBX is up 72.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 245.2%.
MBX Biosciences has posted a net loss over the last twelve months (EPS of -$2.37), so its P/E ratio is not meaningful. MBX Biosciences's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About MBX Biosciences
Company profileMBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Steven L. Hoerter
- Headquarters
- Carmel, IN
- Employees
- 63
- IPO year
- 2024
- Website
- mbxbio.com
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$94.30+72.90%
- Strong buy 3
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.80
MBX Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs MBX |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs MBX |
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs MBX |
| NAMSNewAmsterdam Pharma Company N.V. | 22.13 | -0.63% | $2.59B | vs MBX |
| SUPNSupernus Pharmaceuticals Inc. | 43.05 | +0.51% | $2.51B | vs MBX |
| DYNDyne Therapeutics Inc. | 15.97 | +3.70% | $2.98B | vs MBX |
| HCMHUTCHMED (China) Limited ADR | 14.28 | -2.19% | $2.48B | vs MBX |
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs MBX |
Indexes, lists and sector
MBX Biosciences stock FAQ
What is MBX Biosciences's stock price today?
MBX last traded at $54.54 as of Oct 7, 4:00 PM EDT, down 4.18% on the day. Prices are delayed at least 15 minutes.
When is MBX Biosciences's next earnings date?
MBX Biosciences is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.80.
Who is MBX Biosciences's CEO?
Mr. Steven L. Hoerter is the chief executive officer of MBX Biosciences Inc., which has about 63 employees.
What is the MBX 52-week high?
The 52-week high for MBX is $72.64 and the 52-week low is $12.94. The stock is currently 24.9% below its high.